Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial

Abstract Introduction The dismal prognosis of pancreatic ductal adenocarcinoma (PDAC) highlights the urgent need for novel therapeutic strategies. Immune checkpoint inhibitors (ICIs) seem to be ineffective in most PDAC studies. Therefore, we conducted an open-label, multicenter phase 1/2 study (CA20...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Milan Vošmik, Stanislav John, Josef Dvořák, Beatrice Mohelníková-Duchoňová, Bohuslav Melichar, Radka Lohynská, Aleš Ryška, Aml Mustafa Banni, Johana Krempová, Igor Sirák
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2024-10-01
Colecção:	Oncology and Therapy
Assuntos:	Pancreatic ductal adenocarcinoma Stereotactic radiotherapy Nivolumab
Acesso em linha:	https://doi.org/10.1007/s40487-024-00309-z
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!